Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.815
-0.335 (-10.63%)
At close: Mar 18, 2026, 4:00 PM EDT
2.890
+0.075 (2.66%)
After-hours: Mar 18, 2026, 7:40 PM EDT

Galectin Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
5.685.865.946.626.365.47
Research & Development
23.4736.5732.1331.7423.8217.98
Total Operating Expenses
29.1542.4338.0738.3530.1823.44
Operating Income
-29.15-42.43-38.07-38.35-30.18-23.44
Interest Income
0.160.340.230.0500.07
Interest Expense
-7.12-5.54-2.79-1.03-0.49-0.09
Other Non-Operating Income (Expense)
-1.310.59-0.430.560.14-0.02
Total Non-Operating Income (Expense)
-8.27-4.61-2.99-0.42-0.35-0.04
Pretax Income
-37.42-47.05-41.07-38.78-30.53-23.49
Net Income
-37.44-47.2-44.81-38.87-30.7-23.6
Net Income Attributable to Preferred Dividends
0.140.153.740.10.170.14
Net Income to Common
-37.44-47.2-44.81-38.87-30.7-23.6
Shares Outstanding (Basic)
636260595957
Shares Outstanding (Diluted)
636260595957
Shares Change (YoY)
1.44%3.57%1.29%1.48%2.63%9.17%
EPS (Basic)
-0.59-0.76-0.74-0.65-0.52-0.41
EPS (Diluted)
-0.59-0.76-0.74-0.65-0.52-0.41
Free Cash Flow
-30.62-41.77-32.97-31.06-24.31-20.6
Free Cash Flow Per Share
-0.49-0.67-0.55-0.52-0.42-0.36
EBITDA
-29.13-42.4-38.04-38.32-30.14-23.41
EBIT
-29.15-42.43-38.07-38.35-30.18-23.44
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q